NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple...

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma iMMagine-1 NCT05396885: Phase 2: Study of...

NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma This is a phase II study to determine the...

NCT05338047: Phase 2: Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant This is a...

BOREALIS Trial - CMRG 010 NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients Study of...

MASTER-2 NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2) NCT05231629: Phase 2:...

NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma NDMM RRMM The...

NCT05393804: Phase 2: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell...

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug...